-
07:04:19 PM

RETA Stock News

03/06/23 6:40 AM
Nasdaq : RETA
high short
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
Reata Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in the Barclays Global Healthcare Conference held next week, March 14-16, in Miami, Florida. Reata developed the first and only U.S. Food and Drug Administration...
RHEA-AI
neutral
02/28/23 5:25 PM
Nasdaq : RETA
fda approvalhigh short
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
Reata Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that the U.S. Food and Drug Administration has approved SKYCLARYS™ for the treatment of Friedreich’ s ataxia in adults and adolescents aged 16 years and older. "We are grateful to Friedreich’ s ataxia...
RHEA-AI
very positive
11/10/22 4:42 PM
Nasdaq : RETA
high short
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology& Neurology Conference on November 14– 15, 2022 in New York, NY, and will participate in the Stifel 2022 Healthcare Conference on November 15– 16, 2022 in New York, NY. Important factors that could cause...
RHEA-AI
neutral
11/08/22 6:40 AM
Nasdaq : RETA
earningsclinical trialhigh short
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced financial results for the third quarter of 2022 and provided an update on the Company’ s business operations and clinical development programs. In May 2022, the U.S. Food and Drug Administration accepted our New Drug Application for filing and granted Priority Review...
RHEA-AI
neutral
10/31/22 4:31 PM
Nasdaq : RETA
conferencesearningsclinical trialhigh short
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Company’ s business operations and clinical development programs on November 8, 2022, before the U.S. financial markets open. Reata’ s management will host a...
RHEA-AI
neutral
10/20/22 4:30 PM
Nasdaq : RETA
high short
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich’ s ataxia will be presented at the International Congress for Ataxia Research 2022 being held in Dallas, TX from November 1– 4, 2022.. The abstracts for the oral and...
RHEA-AI
neutral
10/13/22 4:37 PM
Nasdaq : RETA
high short
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’ s New Drug Application for omaveloxolone for the treatment of patients with Friedreich’ s ataxia.
RHEA-AI
neutral
08/09/22 6:45 AM
Nasdaq : RETA
high short
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration informing us that they have extended the review timeline for the New Drug Application for omaveloxolone for the treatment of Friedreich’ s...
RHEA-AI
neutral
08/08/22 6:45 AM
Nasdaq : RETA
earningsclinical trialhigh short
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced financial results for the second quarter of 2022 and provided an update on the Company’ s business operations and clinical development programs. Following the announcement of the positive data from the MOXIe Part 2 study in October 2019, the U.S. Food and Drug...
RHEA-AI
neutral